Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 8/20 | 0.54 |
| ▸ | ALDH1A2 | O94788 | 4/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | USP7 | Q93009 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31367621 | 1.00 | ALDH1A3 (0.54) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367613 | 1.00 | ALDH1A3 (0.54) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367607 | 0.91 | ALDH1A3 (0.63) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367575 | 0.87 | ALDH1A3 (0.49) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367544 | 0.87 | ALDH1A3 (0.52) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367554 | 0.87 | ALDH1A3 (0.49) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367594 | 0.86 | ALDH1A3 (0.57) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367430 | 0.86 | ALDH1A3 (0.68) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367483 | 0.86 | ALDH1A3 (0.68) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A | |
| SCHEMBL31367425 | 0.86 | ALDH1A3 (0.54) | ALDH1A3ALDH1A2ADORA1ALDH1A1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735442-A1 | IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS | Theranib Inc. (CA) | 2026-05-06 | — | — | EP | claimed |
| US-20250011322-A1 | MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A | THERANIB INC. (CA) | 2025-01-09 | — | — | US | claimed |
| EP-4735442-A1 | IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS | Theranib Inc. (CA) | 2026-05-06 | — | — | EP | disclosed |
| US-20250011322-A1 | MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A | THERANIB INC. (CA) | 2025-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011322-A1 | MEDICAL COMPOUND FOR THE INHIBITION OF ALDEHYDE DEHYDROGENASE SUBTYPE 1A | ALDH2, ALDH3A1, ALDH1A1 | ALDH1A3 8/4885ALDH1A2 4/4885ADORA1 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.